A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group And An Open-Label Single-Blind Cohort Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administrered for 12 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatits

Trial Profile

A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group And An Open-Label Single-Blind Cohort Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administrered for 12 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatits

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs NGM 282 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Sponsors NGM Biopharmaceuticals
  • Most Recent Events

    • 24 Oct 2017 Results of a post hoc analysis, presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 19 Oct 2017 According to a NGM Biopharmaceuticals media release, data will be presented at The Liver Meeting 2017 hosted by the American Association for the Study of Liver Diseases (AASLD), with the remainder to be presented at future medical meetings.
    • 19 Oct 2017 According to a NGM Biopharmaceuticals media release, the unprecedented, rapid reduction in steatosis seen in the trial supported the initiation of a Phase 2 expansion phase and company is expecting biopsy data in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top